ATL Ultrasound has received supplemental premarket approval (PMA) from the Food and Drug Administration to market a new scanhead, L12-5, for breast imaging applications on the company's HDI 3000 scanner. The transducer features a new design that improves
ATL Ultrasound has received supplemental premarket approval (PMA) from the Food and Drug Administration to market a new scanhead, L12-5, for breast imaging applications on the company's HDI 3000 scanner. The transducer features a new design that improves near-field focus and image quality, according to the Bothell, WA, vendor. ATL has also received PMAs for breast imaging applications with its Ultramark 9 HDI and HDI 3000 systems.
Mammography Study Compares False Positives Between AI and Radiologists in DBT Screening
May 8th 2025For DBT breast cancer screening, 47 percent of radiologist-only flagged false positives involved mass presentations whereas 40 percent of AI-only flagged false positive cases involved benign calcifications, according to research presented at the recent American Roentgen Ray Society (ARRS) conference.